Free Trial

NewAmsterdam Pharma (NAMS) Earnings Date, Estimates & Call Transcripts

NewAmsterdam Pharma logo
$23.41 -0.59 (-2.46%)
Closing price 04:00 PM Eastern
Extended Trading
$23.42 +0.00 (+0.02%)
As of 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NewAmsterdam Pharma Latest Earnings Summary

Upcoming Q1
Earnings Date
May. 14Before Market OpensEstimated
Actual EPS
(Feb. 26)
-$0.95 Missed By -$0.47
Consensus EPS
(Feb. 26)
-$0.48

NewAmsterdam Pharma posted Q4 2024 earnings on February 26, 2025, reporting an EPS of -$0.95, which missed analysts' consensus estimates of -$0.48 by $0.47. Quarterly revenue was reported to be $12.77 million, above analyst estimates of $3.30 million. With a trailing EPS of -$2.60, NewAmsterdam Pharma's earnings are expected to decrease next year, from ($1.75) to ($1.79) per share.

NAMS Upcoming Earnings

NewAmsterdam Pharma's next earnings date is estimated for Wednesday, May 14, 2025, based off prior year's reporting schedules.

Get NewAmsterdam Pharma Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NewAmsterdam Pharma and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

NAMS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

NAMS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.
Remove Ads

NewAmsterdam Pharma Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20253-$0.51-$0.20-$0.39
Q2 20253-$0.52-$0.34-$0.43
Q3 20253-$0.54-$0.35-$0.46
Q4 20253-$0.55-$0.35-$0.47
FY 202512-$2.12-$1.24-$1.75
Q1 20261-$0.54-$0.54-$0.54
Q2 20261-$0.53-$0.53-$0.53
Q3 20261-$0.54-$0.54-$0.54
Q4 20261-$0.56-$0.56-$0.56
FY 20264($2.17)($2.17)($2.17)
Remove Ads

NewAmsterdam Pharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/14/2025
(Estimated)
-------
2/26/2025Q4 2024-$0.48-$0.95 -$0.47-$0.95$3.30M$12.77M
8/7/2024Q2 2024-$0.59-$0.51+$0.08-$0.61$2.20M$2.28M
5/8/2024Q1 2024-$0.54-$0.62 -$0.08-$0.18$2.95M$1.40M

NewAmsterdam Pharma Earnings - Frequently Asked Questions

NewAmsterdam Pharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 14th, 2025 based off last year's report dates. Learn more on NAMS's earnings history.

In the previous quarter, NewAmsterdam Pharma (NASDAQ:NAMS) missed the analysts' consensus estimate of ($0.48) by $0.47 with a reported earnings per share (EPS) of ($0.95). Learn more on analysts' earnings estimate vs. NAMS's actual earnings.

NewAmsterdam Pharma (NASDAQ:NAMS) has a recorded annual revenue of $45.56 million.

NewAmsterdam Pharma (NASDAQ:NAMS) has a recorded net income of -$176.94 million. NAMS has generated -$2.60 earnings per share over the last four quarters.

NewAmsterdam Pharma's earnings are expected to decrease from ($1.75) per share to ($1.79) per share in the next year.

More Earnings Resources from MarketBeat

Remove Ads


This page (NASDAQ:NAMS) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners